Bahman Sadeghi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Bahman Sadeghi has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Ali Bozorgmehr
Iran Psychiatric Hospital, Iran University of Medical Sciences (IUMS), Tehran, Iran
4 shared publications - Abbas Haghparast
Neuroscience Research Center, Institute of Neuroscience and Cognition, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 shared publications - Ali Shahbazi
Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran
3 shared publications Mohammad Taghi Joghataei
Cellular and Molecular Research Center, Iran University of Medical Sciences (IUMS), Tehran, Iran
3 shared publicationsFatemeh Alizadeh
Department of Genomic Psychiatry and Behavioral Genomics (DGPBG), Roozbeh Hospital, School of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran
2 shared publications- Fatemeh Goshadrou
Department of Physiology, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publications
Latest Publications
- Open Access
- 4 January 2023
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 13, 999199
Cognitive network reconstruction in individuals who use opioids compared to those who do not: Topological analysis of cognitive function through graph model and centrality measures
Introduction: Cognitive dysfunction related to opioid use disorder (OUD) requires investigation of the interconnected network of cognitive domains through behavioral experiments and graph data modeling.Methods: We conducted n-back, selective and divided attention, and Wisconsin card sorting tests and reconstructed the interactive cognitive network of subscales or domains for individuals who use opioids and controls to identify the most central cognitive functions and their connections using graph model analysis. Each two subscales with significant correlations were connected by an edge that incorporated in formation of interactive networks. Each network was analyzed topologically based on the betweenness and closeness centrality measures.Results: Results from the network reconstructed for individuals who use opioids show that in the divided attention module, reaction time and number of commission errors were the most central subscales of cognitive function. Whereas in controls, the number of correct responses and commission errors were the most central cognitive measure. We found that the subscale measures of divided attention module are significantly correlated with those of other tests. These findings corroborate that persons who use opioids show impaired divided attention as higher reaction time and errors in performing tasks. Divided attention is the most central cognitive function in both OUD subjects and controls, although differences were observed between the two groups in various subscales.Discussion: Although equal proportions of males and females may be used in future studies, divided attention and its subscales may be the most promising target for cognitive therapies, treatments and rehabilitation as their improvement can enhance overall cognitive domain performance.
- 4 January 2023
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 13, 999199
Open AccessCognitive network reconstruction in individuals who use opioids compared to those who do not: Topological analysis of cognitive function through graph model and centrality measures
Introduction: Cognitive dysfunction related to opioid use disorder (OUD) requires investigation of the interconnected network of cognitive domains through behavioral experiments and graph data modeling.Methods: We conducted n-back, selective and divided attention, and Wisconsin card sorting tests and reconstructed the interactive cognitive network of subscales or domains for individuals who use opioids and controls to identify the most central cognitive functions and their connections using graph model analysis. Each two subscales with significant correlations were connected by an edge that incorporated in formation of interactive networks. Each network was analyzed topologically based on the betweenness and closeness centrality measures.Results: Results from the network reconstructed for individuals who use opioids show that in the divided attention module, reaction time and number of commission errors were the most central subscales of cognitive function. Whereas in controls, the number of correct responses and commission errors were the most central cognitive measure. We found that the subscale measures of divided attention module are significantly correlated with those of other tests. These findings corroborate that persons who use opioids show impaired divided attention as higher reaction time and errors in performing tasks. Divided attention is the most central cognitive function in both OUD subjects and controls, although differences were observed between the two groups in various subscales.Discussion: Although equal proportions of males and females may be used in future studies, divided attention and its subscales may be the most promising target for cognitive therapies, treatments and rehabilitation as their improvement can enhance overall cognitive domain performance.
- Open Access
- 30 June 2021
- Published by Qeios Ltd
The paradox of theory of mind!
Science folks unanimously agree about a fixed definition for “Theory of Mind”! That I think is a philosophical paradox as theory of mind has this very pivotal cannon of being open in empathizing and understanding different beliefs through attribution...
- 30 June 2021
- Published by Qeios Ltd
Open AccessThe paradox of theory of mind!
Science folks unanimously agree about a fixed definition for “Theory of Mind”! That I think is a philosophical paradox as theory of mind has this very pivotal cannon of being open in empathizing and understanding different beliefs through attribution...
- 22 January 2021
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 71 (7) , 1368-1377
Alteration of TRIM33 Expression at Transcriptional and Translational Levels is Correlated with Autism Symptoms
As a complex neurodevelopmental disorder, autism affects children in three major cognitive domains including social interactions, language learning and repetitive stereotyped behaviors. Abnormal regulation of cell proliferation in the brain during the embryonic period via the TGF-β signaling pathway and TRIM33 gene that encodes a protein with a corepressor and regulatory role in this pathway has been considered as an etiology for autism. Here, we investigated the association of a variation of TRIM33 with autism symptoms at levels of mRNA and protein expression. We used Autism Diagnostic Interview-Revised (ADI-R) and Childhood Autism Rating Scale (CARS) as behavioral diagnostic tools. Normal and autistic children were genotyped for a TRIM33 polymorphism (rs11102807), and then expression was assessed at transcriptional and translational levels. Results demonstrated that the frequency of the homozygous A allele (AA genotype of rs11102807) was significantly higher in children with autism (P < 0.001), whereas carriers of the G allele were mostly among healthy individuals. Children homozygous for the rs11102807 A allele were associated with an increase in CARS and ADI-R scores, indicating a significant correlation with autism symptoms. TRIM33 gene expression at both mRNA (P < 0.01) and protein (P < 0.001) levels was significantly higher in controls compared to autistic children. A remarkable association between higher TRIM33 gene expression at the transcriptional level and lower scores for both CARS and ADI-R was observed in non-autistic children. It seems that rs11102807 modulates the function and expression of the TRIM33 gene, implying that the A allele may increase the risk of autism in children by reducing gene expression and altering the TGF-β signaling pathway.
- 22 January 2021
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 71 (7) , 1368-1377
Alteration of TRIM33 Expression at Transcriptional and Translational Levels is Correlated with Autism Symptoms
As a complex neurodevelopmental disorder, autism affects children in three major cognitive domains including social interactions, language learning and repetitive stereotyped behaviors. Abnormal regulation of cell proliferation in the brain during the embryonic period via the TGF-β signaling pathway and TRIM33 gene that encodes a protein with a corepressor and regulatory role in this pathway has been considered as an etiology for autism. Here, we investigated the association of a variation of TRIM33 with autism symptoms at levels of mRNA and protein expression. We used Autism Diagnostic Interview-Revised (ADI-R) and Childhood Autism Rating Scale (CARS) as behavioral diagnostic tools. Normal and autistic children were genotyped for a TRIM33 polymorphism (rs11102807), and then expression was assessed at transcriptional and translational levels. Results demonstrated that the frequency of the homozygous A allele (AA genotype of rs11102807) was significantly higher in children with autism (P < 0.001), whereas carriers of the G allele were mostly among healthy individuals. Children homozygous for the rs11102807 A allele were associated with an increase in CARS and ADI-R scores, indicating a significant correlation with autism symptoms. TRIM33 gene expression at both mRNA (P < 0.01) and protein (P < 0.001) levels was significantly higher in controls compared to autistic children. A remarkable association between higher TRIM33 gene expression at the transcriptional level and lower scores for both CARS and ADI-R was observed in non-autistic children. It seems that rs11102807 modulates the function and expression of the TRIM33 gene, implying that the A allele may increase the risk of autism in children by reducing gene expression and altering the TGF-β signaling pathway.
- 1 November 2020
- Published by Elsevier in Life Sciences
- Vol. 260, 118345
An integrative gene network-based approach to uncover the cellular and molecular infrastructures of schizophrenia
- 1 November 2020
- Published by Elsevier in Life Sciences
- Vol. 260, 118345
An integrative gene network-based approach to uncover the cellular and molecular infrastructures of schizophrenia
- 1 September 2020
- Published by Elsevier in Neuroscience
- Vol. 444, 196-208
A Novel Link between the Oxytocin Receptor Gene and Impulsivity
- 1 September 2020
- Published by Elsevier in Neuroscience
- Vol. 444, 196-208
A Novel Link between the Oxytocin Receptor Gene and Impulsivity
- 5 September 2018
- Published by Wiley in Hippocampus
- Vol. 28 (10) , 724-734
Chronic ghrelin administration restores hippocampal long‐term potentiation and ameliorates memory impairment in rat model of Alzheimer's disease
Alzheimer's disease (AD), as a common age‐related dementia, is a progressive manifestation of cognitive decline following synaptic failure resulted majorly by senile plaques composed of deposits of amyloid beta (Aβ). Ghrelin is a multifunctional peptide hormone with receptors present in various brain tissues including hippocampus and has been associated with neuroprotection, neuromodulation, and memory processing. Here, we investigated the neuroprotective and therapeutic effects of intracerebroventricular (icv) ghrelin infusion for 2 weeks on passive avoidance learning (PAL), memory retention, and synaptic plasticity in the hippocampal dentate gyrus (DG) and CA1 of both normal rats and Aβ1–42‐induced neurotoxicity in AD model. Male Wistar rats were evaluated for their passive memory performance using a shuttle box while some groups had already received Aβ1–42 and/or chronic ghrelin. Using field potential recording, the induction of short‐ and long‐term potentiation (STP and LTP) was studied in DG granule cells along with the LTP changes in CA1 pyramidal neurons through stimulation of the medial perforant path (mPP) and Schaffer collaterals (SCs), respectively. Our results demonstrated that chronic ghrelin treatment not only improved memory processing and retrieval in normal rats during the PAL task, but also promoted memory retention and alleviated memory loss by amelioration of Aβ1–42‐induced synaptic plasticity impairment in AD subjects through augmentation of field excitatory postsynaptic potential (fEPSP) slope that led to LTP restitution in both the mPP–DG and the CA3–CA1 synapses. Meanwhile, STP was not significantly changed, meaning that although ghrelin enhanced postsynaptic excitability in DG, it did not change presynaptic transmitter release significantly. This suggests the involvement of postsynaptic mechanisms in long‐term ghrelin‐enhanced memory. In conclusion, it can be inferred that chronic ghrelin administration has an auspicious therapeutic value for impaired cognitive performance and memory deficits in AD‐like neuropathology.
- 5 September 2018
- Published by Wiley in Hippocampus
- Vol. 28 (10) , 724-734
Chronic ghrelin administration restores hippocampal long‐term potentiation and ameliorates memory impairment in rat model of Alzheimer's disease
Alzheimer's disease (AD), as a common age‐related dementia, is a progressive manifestation of cognitive decline following synaptic failure resulted majorly by senile plaques composed of deposits of amyloid beta (Aβ). Ghrelin is a multifunctional peptide hormone with receptors present in various brain tissues including hippocampus and has been associated with neuroprotection, neuromodulation, and memory processing. Here, we investigated the neuroprotective and therapeutic effects of intracerebroventricular (icv) ghrelin infusion for 2 weeks on passive avoidance learning (PAL), memory retention, and synaptic plasticity in the hippocampal dentate gyrus (DG) and CA1 of both normal rats and Aβ1–42‐induced neurotoxicity in AD model. Male Wistar rats were evaluated for their passive memory performance using a shuttle box while some groups had already received Aβ1–42 and/or chronic ghrelin. Using field potential recording, the induction of short‐ and long‐term potentiation (STP and LTP) was studied in DG granule cells along with the LTP changes in CA1 pyramidal neurons through stimulation of the medial perforant path (mPP) and Schaffer collaterals (SCs), respectively. Our results demonstrated that chronic ghrelin treatment not only improved memory processing and retrieval in normal rats during the PAL task, but also promoted memory retention and alleviated memory loss by amelioration of Aβ1–42‐induced synaptic plasticity impairment in AD subjects through augmentation of field excitatory postsynaptic potential (fEPSP) slope that led to LTP restitution in both the mPP–DG and the CA3–CA1 synapses. Meanwhile, STP was not significantly changed, meaning that although ghrelin enhanced postsynaptic excitability in DG, it did not change presynaptic transmitter release significantly. This suggests the involvement of postsynaptic mechanisms in long‐term ghrelin‐enhanced memory. In conclusion, it can be inferred that chronic ghrelin administration has an auspicious therapeutic value for impaired cognitive performance and memory deficits in AD‐like neuropathology.
- 1 January 2018
- Published by Elsevier in Behavioural Brain Research
- Vol. 337, 107-113
Involvement of cannabinoid system in the nucleus accumbens on delay-based decision making in the rat
- 1 January 2018
- Published by Elsevier in Behavioural Brain Research
- Vol. 337, 107-113
Involvement of cannabinoid system in the nucleus accumbens on delay-based decision making in the rat
- 1 April 2017
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 41 (S1) , S371
Amelioration of impaired hippocampal cognitive performance in Alzheimer's disease via long-term intervention with ghrelin
Introduction: Alzheimers disease (AD) is a neurodegenerative disorder characterized by loss of memory and cognitive deficits. Ghrelin is a peptide hormone which has been linked to neuroprotection, memory and learning processes.Objectives: This study investigated the effects of ghrelin-induced memory retention on amelioration of cognitive deficits via restoration of long-term potentiation (LTP) and induction of synaptic plasticity in hippocampal CA3, using a rat model of AD induced by amyloid-β (1-42) injection.Methods: Five groups of male rats (230–270 g) including ghrelin-treated (200 ng/rat, [ICV], daily for two weeks), Aβ1-42 injected (5 μL/rat) and Aβ1-42 plus ghrelin-treated animals were designed. Ghrelin was administered after an ICV injection of Aβ1-42. To assess cognitive performance and the motor dysfunction, passive avoidance tests and open-field were performed, respectively. Step-through latency (STL) was evaluated as learning and memory index. Intrahippocampal field potential recordings were done.Results: Results showed that following Aβ1-42 injection, STL and induction of LTP were significantly decreased whereas ICV injection of ghrelin significantly enhanced memory retention by improvement of STL and restitution of LTP in the CA3 with increased EPSP slope and PS amplitude, suggesting the involvement of ghrelin in postsynaptic mechanisms of hippocampal LTP.Conclusions: It was revealed that neuroprotective effects of chronic ghrelin not only can enhance but also can restore LTP in the CA3 area in Aβ-induced AD. Results suggest that ghrelin may be considered as a promising therapeutic agent to alleviate cognitive deficits of AD.Disclosure of interest: The author has not supplied his/her declaration of competing interest.
- 1 April 2017
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 41 (S1) , S371
Amelioration of impaired hippocampal cognitive performance in Alzheimer's disease via long-term intervention with ghrelin
Introduction: Alzheimers disease (AD) is a neurodegenerative disorder characterized by loss of memory and cognitive deficits. Ghrelin is a peptide hormone which has been linked to neuroprotection, memory and learning processes.Objectives: This study investigated the effects of ghrelin-induced memory retention on amelioration of cognitive deficits via restoration of long-term potentiation (LTP) and induction of synaptic plasticity in hippocampal CA3, using a rat model of AD induced by amyloid-β (1-42) injection.Methods: Five groups of male rats (230–270 g) including ghrelin-treated (200 ng/rat, [ICV], daily for two weeks), Aβ1-42 injected (5 μL/rat) and Aβ1-42 plus ghrelin-treated animals were designed. Ghrelin was administered after an ICV injection of Aβ1-42. To assess cognitive performance and the motor dysfunction, passive avoidance tests and open-field were performed, respectively. Step-through latency (STL) was evaluated as learning and memory index. Intrahippocampal field potential recordings were done.Results: Results showed that following Aβ1-42 injection, STL and induction of LTP were significantly decreased whereas ICV injection of ghrelin significantly enhanced memory retention by improvement of STL and restitution of LTP in the CA3 with increased EPSP slope and PS amplitude, suggesting the involvement of ghrelin in postsynaptic mechanisms of hippocampal LTP.Conclusions: It was revealed that neuroprotective effects of chronic ghrelin not only can enhance but also can restore LTP in the CA3 area in Aβ-induced AD. Results suggest that ghrelin may be considered as a promising therapeutic agent to alleviate cognitive deficits of AD.Disclosure of interest: The author has not supplied his/her declaration of competing interest.